Abstract
Introduction: Mitochondrial Encephalomyelopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) is a progressive inherited mitochondrial disorder, characterised by recurrent stroke-like episodes (SLEs), epilepsy and stepwise neurological decline, caused by pathogenic variants in mitochondrial, and rarely, nuclear DNA. Seizures affect approximately 90% of patients and are considered a driver of SLEs. Catamenial worsening of seizures — typically defined as a ≥2-fold increase in seizure frequency or severity at specific phases of the menstrual cycle — has been described in approximately 40% of women with epilepsy but, to our knowledge, has not previously been reported in MELAS.Cases: We report two females with mtDNA-related MELAS (m.3243A>G and m.3252A>G) whose SLEs and seizures developed in the second decade of life and showed a clear perimenstrual (C1) pattern of exacerbation. Both were treated with depot leuprolide acetate (Lucrin) to suppress hypothalamic-pituitary-gonadal cycling, with continuous replacement transdermal sex-steroid. In both cases, GnRH-agonist therapy reduced seizure and SLE frequency, although clinical benefit was only apparent after pituitary down-regulation was complete (typically 2–3 months / two depot doses). Incomplete cycle suppression in one patient required dose escalation; in the other, oestrogen add-back was poorly tolerated and consistently worsened SLEs, with improvement when oestrogen was withdrawn.Conclusion: These cases demonstrate menstrual-cycle-linked exacerbation of epilepsy and SLEs in mtDNA-related MELAS and provide preliminary evidence that complete suppression of cyclic ovarian steroid production with a GnRH agonist can, at least temporarily, reduce disease burden. Despite initial benefit, both patients continued to deteriorate and died of progressive neurological disease.